安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Adverum Biotechnologies - Redefining sight for life.
At Adverum, we are driven to establish ocular gene therapy as a new standard of care for debilitating retinal diseases
- Pipeline - Adverum Biotechnologies
Pipeline Pursuing Paradigm-Changing Gene Therapies Adverum’s promising pipeline moves us ever closer to establishing ocular gene therapy as a new standard of care—with the potential for One And Done™ gene therapy—for debilitating ocular diseases
- Our Technology - Adverum Biotechnologies
Adverum explores new ways to deliver proteins by gene therapy to the eye Gene therapy is a decades old field that focuses on delivery of genetic material to specific cells in the body to treat and even potentially cure diseases in some cases Our current AAV 7m8 vector technology encodes retinal cells to become biofactories that provide robust, sustainable amounts of therapeutic proteins
- Contact Us - Adverum Biotechnologies
We would love to hear from you Please use the following links to engage with one of our team members General Inquiries Investor Inquiries Patient Inquiries Press Inquiries Expanded Access (Compassionate Use)
- Adverum Reminds Stockholders to Tender their Shares into the Offer by . . .
YOUR TENDER MATTERS: TAKE ACTION AND TENDER TODAY We strongly encourage you to accept the offer by Lilly to purchase your Adverum shares by tendering your Adverum shares pursuant to the offer prior to the offer’s expiration time at one minute past 11:59 p m , Eastern time, on December 8, 2025 Regardless of how many shares you own, your tender matters If you need further information or
- Adverum Biotechnologies to Present at BioCentury’s 24th Annual . . .
MENLO PARK, Calif , Sept 07, 2017 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, announced today that Amber Salzman, Ph D , president and chief executive officer, will present at BioCentury’s 24 th Annual NewsMakers in the Biotechnology Industry Conference
- Avalanche Biotechnologies to Present at the NewsMakers in the Biotech . . .
MENLO PARK, Calif , Sept 19, 2014 (GLOBE NEWSWIRE) — Avalanche Biotechnologies, Inc (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that Thomas W Chalberg, Jr , Ph D , Founder and Chief Executive Officer, will present at the 21st
- Adverum Biotechnologies Announces Board and Senior Management Changes
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein The company has collaboration agreements with Regeneron Pharmaceuticals and Editas Medicine
|
|
|